We have discovered a novel compound, NO-1886, which possesses a powerful lipoprotein lipase (LPL) activity-increasing action. Administration of NO-1886 increased LPL activity in the postheparin plasma, adipose tissue, and myocardium of rats, and produced a reduction in plasma triglyceride levels with concomitant elevation ofHDL cholesterol levels. Administration of NO-1886 increased LPL enzyme mass in postheparin plasma and mRNA activity in epididymal adipose tissue, and it was concluded that the mode of action of this compound is stimulation of tissue LPL synthesis. We also conducted longterm studies to assess the impact of increases in LPL activity and HDL levels on the development of atherosclerotic lesions in rats. Administration of NO-1886 for as long as 90 d significantly decreased the degrere of atherosclerotic changes in the coronary arteries of vitamin D2-treated, cholesterol-fed rats. Statistical analysis indicated that increased concentration of HDL is the factor contributing mostly to the prevention ofcoronary artery sclerosis. In summary, the results of our study indicate that compound NO-1886 increases LPL activity, causing an elevation in HDL levels, and that long-term administration of NO-1886 to rats with experimental atherosclerosis provides significant protection against the development of coronary artery lesions. (J. Clin. Invest. 1993. 92:411417.)
Introduction
Recently there has been increasing evidence of an association between triglycerides and increased risk of coronary heart disease (1) . Hypertriglyceridemia per se is an independent risk factor, and this is especially true in certain specific groups of individuals, such as women, those with high plasma LDL (or total) cholesterol levels (2, 3), those with low HDL cholesterol, and diabetics (4, 5) . Thus, a maneuver which would lower plasma triglyceride levels should be ofgreat value in protecting against atherosclerosis. Over the past several years, we have been seeking out compounds that reduce plasma triglyceride levels and have screened compounds synthesized for this purpose.
Hypertriglyceridemia can be caused by either increased synthesis or inadequate removal oftriglycerides or both. We hoped to obtain compounds which would increase lipoprotein lipase (LPL)I activity, an enzyme playing a crucial role for triglyceride removal, because such compounds should enhance triglyceride catabolism via the enzyme's catalytic action and lower the plasma triglyceride levels. In addition, since a precursorproduct relationship appears to exist between triglyceride-rich lipoproteins and HDL levels (6) , compounds that increase LPL activity are expected to increase HDL levels. Among 100 compounds synthesized in our laboratory, we discovered the compound NO-1886 which has a potent LPL activity-increasing action in rats. In this report, we describe the properties of NO-1886 and its effects on plasma lipids. We were also especially interested in learning whether induction of LPL activity would promote or suppress the development ofatherosclerosis. To address this question directly, we administered NO-1886 to rats with experimental atherosclerosis for 90 d and examined its effect on their coronary arteries histochemically. The experiments revealed that NO-1886 prevents the development ofcoronary artery sclerosis in animals with experimental model of the disease.
Effects of a single dose of NO-1886 in normal rats. Changes in plasma lipid concentrations and LPL activity in postheparin plasma were determined after a single administration ofNO-1886 in doses of3, 6, 12, and 25 mg/kg BW to normal rats. Control animals received 5% gum arabic, a diluent ofNO-1886. Based on the results ofa time-course study, blood was collected 4 h after NO-1886 administration. Without prior fasting, blood samples were drawn from the tail vein into tubes containing 1 mg EDTA/ml, and plasma isolated using a refrigerated centrifuge was used for lipid determination. The animals were then injected with heparin (100 U/kg BW) via the tail vein, and blood samples were collected 5 min later. Plasma samples were used to determine LPL and hepatic triglyceride lipase (HTGL) activity. In some experiments, LPL enzyme mass in postheparin plasma was also measured.
Effects of repeated administration of NO-1886 in normal rats. Three groups of normal rats received NO-1886 in daily doses of 25 mg/kg BW for 2, 4, and 8 d, respectively, and control animal experiments were run parallel with the experimental group. Blood samples and samples after heparin injection were collected in the same way as described above. In an attempt to measure LPL activity in both adipose tissue and myocardium, we performed another set of experiments in which no heparin was administered.
Long-term administration of NO-1886 to rats with experimental atherosclerosis. Male Wistar rats, aged 7 wk and weighing 180-200 g, were divided into four groups, a normal control group and three atherogenic diet-fed groups. Normal control rats were fed a standard laboratory chow. The atherogenic diet-fed animals were further divided into (a) controls and rats treated with either (b) low dose (daily dose of 3 mg/kg BW throughout the experimental period) or (c) high dose (30 mg/kg BW) NO-1886. These three groups of rats were given oral vitamin D2 in a daily dose of 350,000 U/kg BW for the initial 4 d and subsequently fed a standard laboratory chow supplemented with 2% cholesterol, 0.5% cholic acid sodium salt, and 0.2% 6-methyl-2-thiouracil for up to 90 d (7, 8) . The animals were given free access to food and tap water. Food consumption was measured daily, and body weight was recorded weekly. At the end of the experimental period, the animals were killed by exsanguination under sodium pentobarbital anesthesia. Blood samples were collected from the posterior vena cava for lipid measurements. The hearts were removed immediately and passed in blind fashion to the pathologist for histological examination. The heart was divided longitudinally into two halves from the ascending aorta to the apex. The ascending aorta, septum, and right and left ventricles were exposed on the cut surfaces. The materials were fixed in 10% neutral buffered formalin, and embedded in paraffin. Thin sections (4 ,um) Plasma lipoprotein analysis. Ultracentrifugation of plasma lipoproteins was carried out using a rotor (L42T; Hitachi Koki Co., Ltd., Tokyo, Japan). The density ofthe samples was adjusted with KBr and KBr solutions of known density. Plasma samples ( 100 u I) were ultracentrifuged at densities of 1.006, 1.019, 1.063, and 1.125 g/ml, respectively, and the lipid concentration of each fraction was measured (9 Measurement of LPL activity and mass in postheparin plasma. LPL activity in postheparin plasma was measured by an immunochemical method described previously ( 10) using glycerol tri[l-'4C]oleate as substrate and selective blocking of hepatic lipase activity with antiserum to rat hepatic lipase. HTGL activity in postheparin plasma was obtained by subtracting LPL activity from total plasma lipase activity. LPL enzyme mass was measured by sandwich ELISA using polyclonal antibodies raised against human LPL, as described previously ( 11) .
Tissue LPL activity. Myocardial LPL activity was measured as reported previously ( 12) . A specimen of myocardium was homogenized in 50 mM NH40H-NH4CI buffer (pH 8.5) containing heparin for 60 min at 0C. The suspension was then centrifuged, and the supernatant was used to measure LPL activity. Adipose tissue LPL activity was measured as described earlier ( 13) . A specimen ofepididymal adipose tissue weighing 100 mg was minced into small pieces and placed in Krebs-Ringer bicarbonate buffer (pH 7.4) in the presence of heparin for 60 min at 370C. The incubation medium was then assayed for LPL activity (heparin-releasable LPL). In some experiments, the residual LPL activity in the adipose tissue was also measured (tissue-bound, heparin-extractable LPL)( 14) to determine total LPL activity in the tissue.
RNA preparation and Northern analysis. Total RNA samples were prepared from rat epididymal adipose tissue by an acid guanidium thiocyanate-phenol chloroform extraction method (15) . Agarose gel electrophoresis of RNA and Northern blotting were carried out by the method described by Sambrook et al. ( 16) . The two molecular probes for the Northern blotting were prepared by reverse transcription and subsequent PCR as follows. First, the mixture of 5.0 Mg of total RNA obtained from rat adipose tissue and 200 pmol of random primer in a final vol of 5.0 Ml was denaturated at 70°C for 3 min and cooled on ice. The synthesis ofthe first strand ofcDNA was initiated by the addition of 5.0 Ml of premixture containing 100 mM Tris-HCI buffer, pH 8.3, 148 mM KCI, 6 mM MgC12, 2 mM dNTP, 20 mM DTT, 16.5 U of RNase inhibitor, and 100 U of reverse transcriptase. This mixture was incubated at 37°C for 1 h, and the reverse transcriptase was denaturated by heating at 98°C for 10 min. A 1.0-Ml aliquot ofthis mixture was used directly as the PCR template. The PCR mixture (100 M1) contained 1.0 Ml oftemplate, 100 pmol ofeach primer, 10 mM Tris -HCl buffer, pH 8.3, 50 mM KCI, 1.5 mM MgCl2, 1.6 mM dNTP, and 2.5 units of Taq DNA polymerase. After overlaying the reaction mixture with 50 Ml of mineral oil, amplification was performed under the standard conditions for PCR ( 16) . To obtain the putative cDNA fragment encoding rat LPL by PCR, two synthesized oligonucleotides, 5'-CGAAGTATTGGGATCCAGAAAC and 5-CTTTCACTCGGATC-CTCTCGAT, were used as the downstream and upstream primer, respectively. These primers correspond to position 655-676 and position 1303-1282 on mouse LPL cDNA (in this paper, the nucleotide sequences were numbered by defining the translation initiation site as + 1). The cDNA fragment obtained (649 bp) was subcloned into pBLUESCRIPT (Stratagene Inc., La Jolla, CA), and its nucleotide sequence was determined by the chain-termination method. We confirmed that the nucleotide sequences of the cDNA fiagment obtained (649 bp) and the cDNA encoding mouse LPL were highly homologous (93.7%). To obtain the putative rat ,B-actin cDNA fragment, the downstream primer (5'-ATGGATGACGATATCGCTGCG) and the upstream primer (5'-GTGCCTAGGGCGGCCCACGAT) were used for PCR. These primers correspond to position 1-22 and position 120-100 on rat fl-actin cDNA, respectively. The nucleotide sequence ofthe cDNA fragment obtained ( 120 bp) was identical to the 1-120 region on the cDNA encoding rat #l-actin where it has low homology with a-actin. These cDNA fragments were radiolabeled by the multipriming method and used for Northern blotting.
Statistical analysis
The results are expressed as means±SD. Comparisons between two groups were analyzed for statistical significance by Student's t test or Postheparin plasma LPL and HTGL activity in NO-1886-treated normal rats. (A) Dose relationship: NO-1886 was administered to rats, and 4 h later the rats were injected with heparin (100 U/kg body wt) via the tail vein. Blood samples were collected 5 min later, and LPL and HTGL activity in postheparin plasma were measured, as described previously ( 10 
Results
Effects ofa single dose ofNO-1886 in normal rats Postheparin plasma LPL activity and mass. Single doses of NO-1886 caused a significant increase in postheparin plasma LPL activity in normal rats. The increases were dose dependent in the 0-25 mg/kg BW range (Fig. 1 A) . The increase peaked 4 h after NO-1886 administration and declined thereafter returning to the baseline level after 24 h (Fig. 1 B) . Single dose of NO-1 886 had no effect on postheparin plasma HTGL activity (Fig. 1) was 17% higher than control rats (P < 0.001). The degree of increase of LPL mass was very similar to that of enzyme activity (Table I) .
Plasma lipids. Single doses ofNO-1 886 to normal rats were followed by significant decreases in plasma triglyceride levels with concomitant increases in HDL cholesterol. Plasma triglycerides fell to their lowest levels in response to 6 mg/kg BW of NO-1886, while HDL cholesterol levels rose as the dose ofNO-1886 was increased to 25 mg/kg BW (Fig. 2) . The changes in both triglyceride and HDL cholesterol levels were associated with changes in postheparin plasma LPL activity. This experiment revealed a significant increase in total cholesterol concentrations in the experimental animals (Fig. 2) .
Further analysis by ultracentrifugation showed that the cholesterol in the LDL fraction did not change and that the in- crease in plasma total cholesterol was primarily a reflection of an increase in the HDL cholesterol fraction (Table II) .
Plasma lipids in relation to postheparin plasma LPL activity. The relationship between preheparin triglyceride and HDL cholesterol levels in plasma and LPL activity in postheparin plasma was assessed in experimental animals given different doses of NO-1886. As shown in Fig. 3 , plasma triglyceride levels were inversely correlated with LPL activity (r = -0.686, P < 0.01, n = 30), while HDL cholesterol levels were positively correlated with the activity of the enzyme (r = 0.678, P < 0.01 ). To further demonstrate that the increase in LPL activity elevated HDL cholesterol levels directly, an experiment was performed in which protamine sulfate was used to block the rise in LPL activity ( 17) in response to administration of NO-1886. Prior intravenous protamine sulfate, 25 mg dissolved in saline/kg BW, inhibited both the rise in HDL cholesterol and the fall in plasma triglyceride levels, both of which were always induced by the compound (Table III) .
Effects ofrepeated administration ofNO-1886 in normal rats
Plasma and tissue lipase activities. Daily administration of NO-1886 to normal rats caused a significant increase in postheparin plasma LPL activity, while HTGL activity in postheparin plasma remained unchanged (Fig. 4) . The LPL activity of epididymal adipose tissue rose gradually and 8 d later the activity of the NO-l 886-treated rats was 2.7 times higher than that of controls (Fig. 5 A) . Myocardial LPL activity was 1.4 times higher in the NO-1886-treated rats than controls (Fig. 5 B) . In another set of experiments, we measured both heparin-releasable and tissue-bound heparin-extractable LPL in adipose tissue. The activities of both fractions of LPL were higher in the NO-1886 treated rats than in the controls (Table IV) (16) . Data are expressed as means±SD (n = 6). Significantly different from the value in the respective control rats: * P < 0.00 1, * P < 0.05, I P < 0.01.
mRNA encoding f3-actin was very similar in all three groups. These findings suggest that NO-1886 increases the amount of LPL protein by enhancing transcription and/or stabilization of the mRNA encoding LPL.
Effects of long-term administration ofNO-1886 on experimental atherosclerosis in the rat The experiment was performed twice, and each result was combined. There were no differences in body weight gain (Table V) and food consumption between NO-1886 treated rats and controls. Plasma lipids. Rats with experimental atherosclerosis exhibited a marked increase in plasma cholesterol. Administration of NO-1886 to rats fed an atherogenic diet increased HDL cholesterol and decreased triglyceride levels (Table V) .
Histopathologicalfindings. 10 of the 11 rats fed a special atherogenic diet were found to have moderate to severe atherosclerotic lesions of their coronary arteries characterized by thickening of the tunica intima with foam cell accumulation and fibrous proliferation (Fig. 8 A) . The tunica intima of the affected coronary arteries contained many oil red 0-stainable lipid droplets and exhibited increased deposition ofacid-mucopolysaccharide when stained with alcian blue, and von Kossa's method revealed calcification and partial rupture of the internal elastic lamina. On the other hand, atherogenic diet-fed 120, NO-1886-treated rats had only very mild to moderate lesions (Fig. 8 B) .
To represent the data statistically, we examined -10 coronary arteries at random and classified the severity of coronary artery sclerosis into five grades on the basis of the extent of the atherosclerotic lesions. The results are summarized in Table  VI . Higher doses of NO-1886 produced greater suppression of the development ofatherosclerotic lesions ofthe coronary arteries (P < 0.01, by two-way cumulative chi-square test). To further define the relative contribution of HDL cholesterol, non-HDL cholesterol (total cholesterol -HDL-C), and triglycerides to protection from coronary artery sclerosis, multiple regression analysis was performed. The severity of coronary artery sclerosis was assessed on the basis of foam cell accumulation and graded as follows: " " for grade 1, "2" for grade 2, "3" for grade 3, "4" for grade 4, and "5" for grade 5 
